Terms: = Lung cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Treatment
86 results:
1. The innovative checkpoint inhibitors of lung adenocarcinoma, cg09897064 methylation and ZBP1 expression reduction, have implications for macrophage polarization and tumor growth in lung cancer.
Wang A; Zheng WS; Luo Z; Bai L; Zhang S
J Transl Med; 2024 Feb; 22(1):173. PubMed ID: 38369516
[TBL] [Abstract] [Full Text] [Related]
2. Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.
Sui Q; Hu Z; Liang J; Lu T; Bian Y; Jin X; Li M; Huang Y; Yang H; Wang Q; Lin Z; Chen Z; Zhan C
Cancer Lett; 2024 Jan; 581():216497. PubMed ID: 38008395
[TBL] [Abstract] [Full Text] [Related]
3. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K; Sabari JK; Haura EB; Shu CA; Spira A; Salgia R; Reckamp KL; Sanborn RE; Govindan R; Bauml JM; Curtin JC; Xie J; Roshak A; Lorenzini P; Millington D; Thayu M; Knoblauch RE; Cho BC
Lung Cancer; 2023 Apr; 178():166-171. PubMed ID: 36868177
[TBL] [Abstract] [Full Text] [Related]
4. In vitro antioxidant, anti-inflammatory, and anticancer activities of mixture Thai medicinal plants.
Jongrungraungchok S; Madaka F; Wunnakup T; Sudsai T; Pongphaew C; Songsak T; Pradubyat N
BMC Complement Med Ther; 2023 Feb; 23(1):43. PubMed ID: 36765341
[TBL] [Abstract] [Full Text] [Related]
5. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell lung cancer and Other Advanced Solid Tumors.
Kollmannsberger C; Hurwitz H; Bazhenova L; Cho BC; Hong D; Park K; Reckamp KL; Sharma S; Der-Torossian H; Christensen JG; Faltaos D; Potvin D; Tassell V; Chao R; Shapiro GI
Target Oncol; 2023 Jan; 18(1):105-118. PubMed ID: 36459255
[TBL] [Abstract] [Full Text] [Related]
6. treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence.
Bowes K; Jovanoski N; Brown AE; Di Maio D; Belleli R; Chadda S; Abogunrin S
Med Oncol; 2022 Oct; 40(1):4. PubMed ID: 36308605
[TBL] [Abstract] [Full Text] [Related]
7. Montelukast ameliorated pemetrexed-induced cytotoxicity in hepatocytes by mitigating endoplasmic reticulum (ER) stress and nucleotide oligomerization domain-like receptor protein 3 (NLRP3) activation.
Fei Z; Zhang L; Wang L; Jiang H; Peng A
Bioengineered; 2022 Mar; 13(3):7894-7903. PubMed ID: 35291928
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
Zhang J; Wang Y; Liu Z; Wang L; Yao Y; Liu Y; Hao XZ; Wang J; Xing P; Li J
Thorac Cancer; 2021 Dec; 12(24):3407-3415. PubMed ID: 34751504
[TBL] [Abstract] [Full Text] [Related]
9. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J
BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250
[TBL] [Abstract] [Full Text] [Related]
10. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with cancer.
Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
[TBL] [Abstract] [Full Text] [Related]
11. CCAAT enhancer binding protein α suppresses proliferation, metastasis, and epithelial-mesenchymal transition of ovarian cancer cells via suppressing the Wnt/β-catenin signaling.
Zhang LM; Li M; Tian CC; Wang TT; Mi SF
Neoplasma; 2021 May; 68(3):602-612. PubMed ID: 33780265
[TBL] [Abstract] [Full Text] [Related]
12. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL
Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611
[TBL] [Abstract] [Full Text] [Related]
13. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line treatment in Patients with Advanced Non-Small-Cell lung cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
[TBL] [Abstract] [Full Text] [Related]
14. Non-myxoma neoplastic cerebral aneurysms: A systematic review.
Nussbaum ES; Torok CM; Khalil ZM; Pederson JM
J Clin Neurosci; 2020 Dec; 82(Pt B):200-206. PubMed ID: 33246908
[TBL] [Abstract] [Full Text] [Related]
15. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Paty J; Sandin R; Reisman A; Wu YL; Migliorino MR; Zhou X; Cheng Y; Lee KH; Nakagawa K; Niho S; Corral J; Płużański A; Linke R; Meyers O; Mok TS
Future Oncol; 2021 Mar; 17(7):783-794. PubMed ID: 33164569
[No Abstract] [Full Text] [Related]
16. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Li Y; Liu Y; Zhao N; Yang X; Li Y; Zhai F; Zang X; Cui W
Cell Death Dis; 2020 Sep; 11(9):753. PubMed ID: 32934224
[TBL] [Abstract] [Full Text] [Related]
17. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract] [Full Text] [Related]
18. lung cancer and Immunity Markers.
Lim RJ; Liu B; Krysan K; Dubinett SM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2423-2430. PubMed ID: 32856614
[TBL] [Abstract] [Full Text] [Related]
19. International real-world study of DLL3 expression in patients with small cell lung cancer.
Rojo F; Corassa M; Mavroudis D; Öz AB; Biesma B; Brcic L; Pauwels P; Sailer V; Gosney J; Miljkovic D; Hader C; Wu M; Almarez T; Penault-Llorca F
Lung Cancer; 2020 Sep; 147():237-243. PubMed ID: 32745892
[TBL] [Abstract] [Full Text] [Related]
20. Real-world osimertinib for
Imamura F; Kimura M; Yano Y; Mori M; Suzuki H; Hirashima T; Ihara S; Komuta K; Shiroyama T; Nagatomo I; Kumagai T
Future Oncol; 2020 Jul; 16(21):1537-1547. PubMed ID: 32662665
[No Abstract] [Full Text] [Related]
[Next]
